Abliva intends to start a pivotal KL1333 study second half 2021 — Hadean Ventures Home…
Continue Reading-
Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial
Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial — Hadean…
Continue Reading -
Pewin Member Highlight 2020: Ingrid Teigland Akay
Pewin Member Highlight 2020: Ingrid Teigland Akay — Hadean Ventures Home Portfolio Team Impact Investors…
Continue Reading -
Abliva receives positive FDA feedback on its KL1333 development plan
Abliva receives positive FDA feedback on its KL1333 development plan — Hadean Ventures Home Portfolio…
Continue Reading -
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss
Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss — Hadean…
Continue Reading -
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of first-in-class mPGES-1 inhibitor GS-248 for systemic sclerosis
Gesynta raises SEK 190 million in round led by Hadean Ventures to accelerate development of…
Continue Reading -
€1.9M EU funding takes Nelli® available for all epilepsy patients
€1.9M EU funding takes Nelli® available for all epilepsy patients — Hadean Ventures Home Portfolio…
Continue Reading -
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
Abliva completes the directed issue of MSEK 20 to Hadean Ventures — Hadean Ventures Home…
Continue Reading -
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial
Oncoinvent Announces Dosing of First Patient with Radspherin® in a Second Phase 1 Clinical Trial…
Continue Reading -
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial
Oncoinvent Announces Dosing of First Patient with Radspherin® in Phase 1 Clinical Trial — Hadean…
Continue Reading